ARD-101 — Topline data
Q3 2026
Assessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed determination of next stepsSource filing
AARDVARK THERAPEUTICS INC · Data as of 2026-09-08
Q3 2026
Assessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed determination of next stepsSource filing
2H 2026
Preliminary or interim data: 2H 2026Source filing